The Japanese drug maker Eisai Co is looking to hire as many as 100 people in India, reports said.
Eisai plans to hire 100 staff including 20 scientists to man its upcoming research and development center in the eastern city of Visakhapatnam, Andhra Pradesh state.
Once completed, the $50 million R&D facility will be Eisai’s first laboratory in Asia outside Japan.
Eisai’s new R&D facility is expected to speed the development of medications for the Indian market besides acting a hub for producing new drugs for the global market.
Eisai’s Aricept is the world’s best-selling Alzheimer’s disease treatment.
India’s domestic pharmaceutical industry, worth about $11 billion in the year ended March 2009, will expand to about $30 billion by 2020, accounting firm PricewaterhouseCoopers LLP said in an April report.
AstraZeneca, the Anglo-Swedish drug maker, has recently announced plans to double its workforce in India in the next two years.
AstraZeneca, which recently launched Bristol-Myers Squibb’s most advanced anti-diabetes therapy Onglyza (saxagliptin) in India, now wants to ramp up Indian operations by boosting its workforce in the country, reports said.
Of late, Daiichi-Ranbaxy has also announced plans to boost its sales team by 50% by hiring about 1,500 marketing executives to focus on India’s rural areas.
Ranbaxy, which currently has a sales team of nearly 3,000, would augment its marketing force to penetrate deeper into the rural markets, reports said.
The company will hire regional managers and area managers by July besides massively recruiting medical representatives to focus on smaller cities and towns.
Despite serious layoffs in the developed markets, an increasing number of pharma multinational companies (MNC) from Europe and the US are planning to bolster their workforce in India. Big Pharma, which is incurring steady losses in the major markets, see the emerging pharma destinations like India as valuable hedges to offset their setbacks.
Recently, Bayer Schering Pharma AG, Germany’s largest pharmaceutical company announcedplan to double its sales force in India.
Over 20% of Bayer’s healthcare division’s 2009 sales were generated from the Asia Pacific region.
Bayer Schering Pharma is currently one of the largest pharmaceuticals suppliers in China.
Becton, Dickinson and Company (BD), one of the world’s leading syringe suppliers, has announced its plans to add nearly 100 people its India team each year.
Becton Dickinson is proposing significant expansions in the manufacturing operations. The company is planning to transfer 10 manufacturing lines of IV catheter from Sweden to India.
The company has also plans to expand its marketing operations as well by adding more workforce, reports said quoting senior official from Becton.
Employment opportunities are worldwide, tough to come by right now. Unable to cope with the recession heat, drug giants may be drastically cutting down their staff everywhere else. But it is exactly the opposite what pharma MNCs are doing in India.
Pharma sector employment opportunities better as Aventis, GSK, Merck looking fill hundreds of jobs in field & marketing.
Aventis Pharma Ltd, the Indian arm of the French drug maker Sanofi-Aventis, which has been operating in India for several years, suddenly turned aggressive about the Indian market. Now they want to fill jobs and augment Indian sales force by 700-800 in the next couple of years.
Sanofi-Aventis will consider all possibilities including acquiring a local firm to consolidate its presence in the country to realize the goal of positioning itself in the top five league, he said.
GlaxoSmithKline (GSK) is another leading European pharma major looking to hire in India. The world’s second largest drug company plans to bolster its field force by employing at east 200 people. GSK India, which currently has 2,250-strong sales and marketing team, wants to enhance its field-force support in its vaccines, oncology and other speciality segments, the company said recently while announcing quarterly financial performance in India
GSK India’s net profit for the three months ended December 31, 2008 more than doubled over the net profit clocked in the corresponding period last year, due to Rs 119 crore exceptional items from the sale of shares and other income from investments, a one-time gain, a company spokesperson said.
For the year ended December 31, 2008, GSK Pharma posted a net profit of Rs 576 crore compared with a net profit of Rs 537 crore in the corresponding period of the previous year. It clocked a total income of Rs 1,708 crore for the year under review against Rs 1,621 crore in the corresponding period last year.
Recently, GSK Chief Executive, Mr Andrew Witty said that the company planned to cut medicine prices in poor countries and invest about 20 per cent of its profit from such markets into healthcare infrastructure.
Merck Sharpe & Dohme Pharmaceuticals (MSD), the Indian subsidiary of the world’s fifth largest drug firm Merck Inc, is another case in point of pharma MNCs looking at expansion and new job openings in India.
Merck, which exited in India markets decades ago fearing IP back lash due to an increasingly pro-generic regulatory climate, is now back in India with big plans.
MSD Pharmaceuticals wants to be one of the five top players in India by 2015 as it sees the IP environs improve following India’s adherence to Product Patent regime since the beginning of the year 2005.